These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

350 related items for PubMed ID: 8340944

  • 1. Phase I trial of granulocyte-macrophage colony-stimulating factor plus high-dose cyclophosphamide given every 2 weeks: a Cancer and Leukemia Group B study.
    Lichtman SM, Ratain MJ, Van Echo DA, Rosner G, Egorin MJ, Budman DR, Vogelzang NJ, Norton L, Schilsky RL.
    J Natl Cancer Inst; 1993 Aug 18; 85(16):1319-26. PubMed ID: 8340944
    [Abstract] [Full Text] [Related]

  • 2. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy.
    Tepler I, Cannistra SA, Frei E, Gonin R, Anderson KC, Demetri G, Niloff J, Goodman H, Muntz H, Muto M.
    J Clin Oncol; 1993 Aug 18; 11(8):1583-91. PubMed ID: 8101563
    [Abstract] [Full Text] [Related]

  • 3. Phase I trial of etoposide, carboplatin, and GM-CSF in extensive small-cell lung cancer: a Cancer and Leukemia Group B study (CALGB 8832).
    Luikart SD, Herndon JE, Hollis DR, MacDonald M, Maurer LH, Crawford J, Clamon GH, Wright J, Perry MC, Ozer H, Green MR.
    Am J Clin Oncol; 1997 Feb 18; 20(1):24-30. PubMed ID: 9020283
    [Abstract] [Full Text] [Related]

  • 4. Abrogating chemotherapy-induced myelosuppression by recombinant granulocyte-macrophage colony-stimulating factor in patients with sarcoma: protection at the progenitor cell level.
    Vadhan-Raj S, Broxmeyer HE, Hittelman WN, Papadopoulos NE, Chawla SP, Fenoglio C, Cooper S, Buescher ES, Frenck RW, Holian A.
    J Clin Oncol; 1992 Aug 18; 10(8):1266-77. PubMed ID: 1634916
    [Abstract] [Full Text] [Related]

  • 5. A dose intensity study of FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy and Escherichia coli-derived granulocyte-macrophage colony-stimulating factor (GM-CSF) in advanced breast cancer patients.
    O'Shaughnessy JA, Denicoff AM, Venzon DJ, Danforth D, Pierce LJ, Frame JN, Bastian A, Ghosh B, Goldspiel B, Miller L.
    Ann Oncol; 1994 Oct 18; 5(8):709-16. PubMed ID: 7826903
    [Abstract] [Full Text] [Related]

  • 6. Granulocyte-macrophage colony-stimulating factor (GM-CSF) priming of high-dose etoposide and cyclophosphamide: a pilot trial.
    Bernstein SH, Christiansen NP, Fay JP, Brown R, Herzig R, Frankel S, Blumenson L, Herzig GP.
    Exp Hematol; 1996 Oct 18; 24(12):1363-8. PubMed ID: 8913281
    [Abstract] [Full Text] [Related]

  • 7. Comparative effects of granulocyte-macrophage colony-stimulating factor and granulocyte colony-stimulating factor after high-dose cyclophosphamide cancer therapy.
    Bregni M, Siena S, Di Nicola M, Dodero A, Peccatori F, Ravagnani F, Danesini G, Laffranchi A, Bonadonna G, Gianni AM.
    J Clin Oncol; 1996 Feb 18; 14(2):628-35. PubMed ID: 8636780
    [Abstract] [Full Text] [Related]

  • 8. Double-cycle high-dose chemotherapy with peripheral blood stem cells and hematopoietic growth factor support in patients with advanced solid tumor. A pilot study by the Hong Kong Biotherapy Group.
    Yeung AW, Pang YK, Tsang YC, Wong SW.
    Cancer; 1994 Apr 01; 73(7):1960-70. PubMed ID: 7511042
    [Abstract] [Full Text] [Related]

  • 9. Phase I trial of infusional cyclophosphamide, doxorubicin, and etoposide plus granulocyte-macrophage colony stimulating factor (GM-CSF) in non-Hodgkin's lymphoma.
    Sparano JA, Negassa A, Lansigan E, Locke R, De Silva CR, Wiernik PH.
    Med Oncol; 2005 Apr 01; 22(3):257-67. PubMed ID: 16110137
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Sequential interleukin-3 and granulocyte-colony stimulating factor prior to and following high-dose etoposide and cyclophosphamide: a phase I/II trial.
    Bernstein SH, Fay JP, Christiansen NP, Pinero L, Shah D, Stephan M, Herzig GP.
    Clin Cancer Res; 1997 Sep 01; 3(9):1519-26. PubMed ID: 9815838
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A phase I study of sequential versus concurrent interleukin-3 and granulocyte-macrophage colony-stimulating factor in advanced breast cancer patients treated with FLAC (5-fluorouracil, leucovorin, doxorubicin, cyclophosphamide) chemotherapy.
    O'Shaughnessy JA, Venzon DJ, Gossard M, Noone MH, Denicoff A, Tolcher A, Danforth D, Jacobson J, Keegan P, Miller L, Chow C, Goldspiel B, Cowan KH.
    Blood; 1995 Oct 15; 86(8):2913-21. PubMed ID: 7579383
    [Abstract] [Full Text] [Related]

  • 15. Randomized double-blind prospective trial to evaluate the effects of sargramostim versus placebo in a moderate-dose fluorouracil, doxorubicin, and cyclophosphamide adjuvant chemotherapy program for stage II and III breast cancer.
    Jones SE, Schottstaedt MW, Duncan LA, Kirby RL, Good RH, Mennel RG, George TK, Snyder DA, Watkins DL, Denham CA, Hoyes FA, Rubin AS.
    J Clin Oncol; 1996 Nov 15; 14(11):2976-83. PubMed ID: 8918495
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. The efficacy of recombinant human granulocyte colony-stimulating factor and recombinant human granulocyte macrophage colony-stimulating factor in permitting the administration of higher doses of cyclophosphamide in a doxorubicin-cyclophosphamide combination. An NSABP pilot study in patients with metastatic or high-risk primary breast cancer. National Surgical Adjuvant Breast and Bowel Project.
    Mamounas EP, Anderson S, Wickerham DL, Clark R, Stoller R, Hamm JT, Stewart JA, Bear HD, Glass AG, Bornstein R.
    Am J Clin Oncol; 1994 Oct 15; 17(5):374-81; discussion 382. PubMed ID: 7522393
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Two phase I studies of carboplatin dose escalation in chemotherapy-naive ovarian cancer patients supported with granulocyte-macrophage colony-stimulating factor.
    Rusthoven J, Levin L, Eisenhauer E, Mazurka J, Carmichael J, O'Connell G, Bryson P, Hirte H, Koski B.
    J Natl Cancer Inst; 1991 Dec 04; 83(23):1748-53. PubMed ID: 1770554
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.